After Gossamer Bio (GOSS) announced that its TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension, or PAH, achieved its primary endpoint, BTIG analyst Julian Harrison upgraded Aerovate Therapeutics (AVTE) to Buy from Neutral with a $27 price target, citing his view that Gossamer’s validation for DPI administered TKIs in PAH as "a safe and technically viable approach" is to "Aerovate’s benefit." He also contends that Gossamer’s DPI seralutinib "does not look like a competitive disease modifying" therapy and therefore likely does not put pressure on the AV-101 opportunity at this time. He increased his peak market penetration forecast to 45% from 40% following Gossamer’s update, Harrison noted.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AVTE:
- Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
- Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
- Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022